The Use of Radiolabelled Monoclonal Antibodies in the Diagnosis of Colorectal Carcinomas
Tóm tắt
The development of monoclonal antibodies (mAbs) using the hybridoma technology has led to new approaches for imaging cancer patients. mAbs against carcinoembryonic antigen (CEA) or TAG-72, two tumour-associated antigens expressed by the vast majority of colorectal adenocarcinomas, have been successfully conjugated with various radionuclides such as I-131, I-123, Tc-99m and In-111. Clinical trials have demonstrated the relative safety of these molecules as well as their unique ability to identify lesions not detected by conventional radiographic imaging modalities. In-111 satumomab pendetide was the first clinically approved murine mAb conjugate for imaging colorectal and ovarian carcinomas. Clinical experience suggests a useful role for In-111 satumomab pendetide in the post-operative evaluation of patients with suspected recurrent colorectal cancer, as well as the potential for altering patient management and possibly a reduction in the costs associated with the work-up and evaluation of patients with occult recurrent colorectal carcinomas. The routine clinical application of these murine-based mAbs is limited by the induction of host immune responses, notably the formation of human anti-mouse antibodies. These have been shown to significantly alter the biodistribution and pharmacokinetics of In-111 satumomab pendetide, leading to a reduction in tumour targeting effectiveness. Alternatives such as the development of chimaeric antibodies or entirely human mAbs, or the use of the nonimmunogenic portion of the mAb, i.e. Fab’ fragments, have been proposed and are currently under investigation. Tc-99m arcitumomab, an Fab’ fragment of IMMU-4, an anti-CEA monoclonal antibody, has recently been approved for imaging in colorectal cancer.
Tài liệu tham khảo
Gelfand DW, Ott DJ. Colon cancer screening: where radiology fits in. Diagn Imag 1993 July; 75–7
Blot WJ. The epidemiology of cancer. In: Cecil textbook of medicine. Philadelphia: WB Saunders, 1992: 1027–32
Levin B. Neoplasms of the large and small intestine. In: Cecil textbook of medicine. Philadelphia: WB Saunders, 1992: 713–20
Collier BD, Abdel-Nabi H, Doerr RJ, et al. Immunoscintigraphy performed with In-111-labeled CYT-103 in the management of colorectal cancer: comparison with CT. Radiology 1992; 185: 179–86
Doerr RJ, Abdel-Nabi H, Baker JM, et al. Detection of primary colorectal cancer with indium 111 monoclonal antibody B72.3. Arch Surg 1990; 125: 1601–5
Galandiuk S. Immunoscintigraphy in the surgical management of colorectal cancer. J Nucl Med 1993; 34: 541–44
Galandiuk S, Wieand HS, Moertel CG, et al. Patterns of recurrence after curative resection of carcinoma of the colon and rectum. Surg Gynecol Obstet 1992; 174: 27–32
Collier BD, Foley WD. Current imaging strategies for colorectal cancer. J Nucl Med 1993; 34: 537–40
Nabi HA, Doerr RJ. Radiolabeled monoclonal antibody imaging (immunoscintigraphy) of colorectal cancers: current status and future perspectives. Am J Surg 1992; 163: 448–56
Moertel CG, Fleming TR, Macdonald JS, et al. An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. JAMA 1993; 270: 943–7
Northover JMA. Carcinoembryonic antigen and recurrent colorectal cancer. Gut 1986; 27: 117–22
Sandler RS, Freund DA, Herbst CA, et al. Cost-effectiveness of post-operative carcinoembryonic antigen monitoring in colorectal cancer. Cancer 1984; 53: 193–8
Huband JE, Hodson NJ, Parsons CA. The use of computed tomography in recurrent rectal tumors. Radiology 1980; 134: 677–82
Thompson WM, Halvorsen RA. Computed tomographic staging of gastrointestinal malignancies. Part II. The small bowel, colon and rectum. Invest Radiol 1987; 22: 96–105
Thompson WM, Halvorsen RA, Foster Jr WL, et al. Preoperative and postoperative CT staging of rectosigmoid carcinoma. AJR Am J Roent 1986; 146: 703–10
Freeny PC, Marks WM, Ryan JA, et al. Colorectal carcinoma evaluation with CT: preoperative staging and detection of postoperative recurrence. Radiology 1986; 158: 347–53
Kelvin FM, Korobkin M, Heaston DK, et al. The pelvis after surgery for rectal carcinoma: serial CT observations with emphasis on nonneoplastic features. AJR Am J Roent 1983; 141: 959–64
Lee JKT, Santley RJ, Sagel SS, et al. CT appearance of the pelvis after abdomino-perineal resection for rectal carcinoma. Radiology 1981; 141: 737–41
Kohler G, Milstein C. Continuous culture of fused cells secreting antibody of predefined specificity. Nature 1975; 256: 495–7
Goldenberg DM, Larson SM. Radioimmunodetection in cancer identification. J Nucl Med 1992; 33: 803–14
Doerr RJ, Abdel-Nabi H, Merchant B. Indium-111 ZCE 025 immunoscintigraphy in occult recurrent colorectal cancer with elevated carcinoembryonic antigen level. Arch Surg 1990; 125: 226–9
Haseman MK, Brown DW, Keeling CA, et al. Radioimmunodetection of occult carcinoembryonic antigen-producing cancer. J Nucl Med 1992; 33: 1750–7
Doerr RJ, Herrera L, Abdel-Nabi HA. In-111 CYT-103 monoclonal antibody imaging in patients with suspected recurrent colorectal cancer. Cancer 1993; 71: 4241–7
Colcher D, Horan Hand P, Nuti M, et al. A spectrum of monoclonal antibodies reactive with human mammary tumor cells. Proc Natl Acad Sci USA 1981; 78: 3199–203
Carrasquillo JA, Sugarbaker P, Colcher D, et al. Radioimmuno-scintigraphy of colon cancer with iodine-131 labeled B72.3 monoclonal antibody. J Nucl Med 1988; 29: 1022–30
Maguire RT, Schmelter RJ, Pascucci VL, et al. Immunoscintigraphy of colorectal adenocarcinoma: results with site-specific radiolabeled B72.3 (111In-CYT-103). Antibody Immunoconj Radiopharm 1989; 2: 257–69
Doerr RJ, Abdel-Nabi H, Krag D, et al. Radiolabeled antibody imaging in the management of colorectal cancer: results of a multicenter clinical study. Ann Surg 1991; 214: 118–24
Carrasquillo JA, Sugarbaker P, Colcher D, et al. Peritoneal carcinomatosis: imaging with intraperitoneal injection of I-131 labeled B72.3 monoclonal antibody. Radiology 1988; 167: 35–40
Rodwell JD, Alvares VL, Lee C, et al. Site specific covalent modification of monoclonal antibodies: in vivo and in vitro evaluations. Proc Natl Acad Sci USA 1986; 83; 2632–6
Nabi HA. Radiolabeled antibodies in clinical nuclear medicine: a technology coming of age. In: Freeman LM, editor. Nuclear Medicine Annual 1993. New York: Raven Press, 1993: 1–27
Nabi HA. Enhanced tumor detection with SPECT, and its contribution in the evaluation of patients with colorectal carcinoma by use of In-111 monoclonal antibody scintigraphy. Radiology 1993; 189: 334
Neal CE, Abdel-Nabi H. Clinical immunoscintigraphy of recurrent colorectal carcinoma. Appl Radiol 1994: 32–9
Corman ML, Galandiuk S, Block GE, et al. Immunoscintigraphy with 111In-satumomab pendetide in patients with colorectal adenocarcinoma: performance and impact on clinical management. Dis Colon Rectum 1994; 37: 129–37
Abdel-Nabi H, Doerr RJ, Chan HW, et al. In-Ill labeled monoclonal antibody immunoscintigraphy in colorectal carcinoma patients: safety, sensitivity, and preliminary clinical applications. Radiology 1990; 175: 163–71
Abdel-Nabi H, Doerr RJ. Detection of recurrent colorectal cancer: an algorithm for immunoscintigraphy. Appl Radiol 1994 Dec; 11–16
Smith LM, Unger M, Bartholomew R. Antimouse responses to monoclonal antibody (MoAb) therapy in human patients. J Nucl Med 1986; 27: 942
Shawler DL, Bartholomew RM, Smith LM, et al. Human immune response to multiple injections of murine monoclonal IgG. J Immunol 1985; 135: 1530–5
Schroff RW, Foon KA, Beatty SM, et al. Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy. Cancer Res 1985; 45: 879–85
Cytogen Corporation/Knoll Pharmaceutical Company. Onco-Scint CR/OV kit (satumomab pendetide). Prescribing information 1992
Perkins AC, Pimm MV, Powell MC. The implications of patients antibody response for the clinical usefulness of immunoscintigraphy. Nucl Med Commun 1988; 9: 273–82
Abdel-Nabi H, Harwood SJ, Collier BD, et al. Repeated administration of OncoScint™ (In-111-CYT-103) in colorectal carcinoma patients: interim report of safety, efficacy and HAMA development. J Nucl Med 1993; 34: 213P
Abdel-Nabi H, Maroli A. HAMA response to repeated administration of In-111 satumomab pendetide (OncoScint™): frequency and patterns of development [abstract]. Proc Am Assoc Cancer Res 1994; 35: 218
Hansen HJ, LaFontaine G, Newman ES, et al. Solving the problem of antibody interference in commercial ‘sandwich’ type immunoassay of carcinoembryonic antigen. Clin Chem 1989; 35: 146–51
Khazaeli MB, Saleh MN, Liu TP, et al. Pharmacokinetics and immune response of 131I-chimeric mouse/human B72.3 (human gamma4) monoclonal antibody in humans. Cancer Res 1991; 51: 5461–6
Buchegger F, Mach JP, Pèlegrin A, et al. Radiolabeled chimeric anti-CEA monoclonal antibody compared with the original mouse monoclonal antibody for surgically treated colorectal carcinoma. J Nucl Med 1995; 36: 420–9
Bosslet K, Lüben G, Schwarz A, et al. Immunohistochemical localization and molecular characteristics of three monoclonal antibody defined epitopes on carcinoembryonic antigen (CEA). Int J Cancer 1985; 36: 75–84
Schwarz A, Steinsträsser A. A novel approach to Tc-99m labeled monoclonal antibodies. J Nucl Med 1987; 38: 721
Lind P, Lechner P, Arian-Schad K, et al. Anti-carcinoembryonic antigen immunoscintigraphy (technetium-99m monoclonal antibody BW 431/26) and serum CEA levels in patients with suspected primary and recurrent colorectal carcinoma. J Nucl Med 1991; 32: 1319–25
Siccardi AG, Buraggi GL, Callegaro L, et al. Immunoscintigraphy of adenocarcinomas by means of radiolabeled F(ab′)2 fragments of an anti-carcinoembryonic antigen monoclonal antibody: a multicenter study. Cancer Res 1989; 49: 3095–4103
Moffat FL, Pinsky CM, Petrelli N, et al. Clinical utility of imaging with the IMMU-4 99mTc-Fab′ fragment in patients undergoing surgery for carcinoma of the colon or rectum [abstract]. Proceedings of the Society of Surgical Oncology Meeting: 1995 Mar 23–26; Boston
Lechner P, Lind P, Binter G, et al. Anti-carcinoembryonic antigen immunoscintigraphy with a 99mTc Fab′ fragment (Immu4™) in primary and recurrent colorectal cancer: a prospective study. Dis Colon Rectum 1993; 36: 930–5
Podoloff DA, Patt YZ, Curley SA, et al. Imaging of colorectal carcinoma with technetium 99m radiolabeled Fab′ fragments. Semin Nucl Med 1993; 2: 89–98
Patt YZ, Podoloff DA, Curley S, et al. Technetium-99m labeled IMMU-4, a monoclonal antibody against carcinoembryonic antigen, for imaging of occult recurrent colorectal cancer in patients with rising serum carcinoembryonic antigen levels. J Clin Oncol 1994; 12: 489–95
Moffat Jr FL, Vargas-Cuba RD, Serafini AN, et al. Radioimmunodetection of colorectal carcinoma using technetium-99m labeled Fab′ fragments of the IMMU-4 anti-carcinoembryonic antigen monoclonal antibody. Cancer 1994; 73: 836–45
Behr T, Becker W, Hannappel E, et al. Targeting of liver metastases of colorectal cancer with IgG F(ab′)2, and Fab anti-carcinoembryonic antigen antibodies labeled with 99mTc: the role of metabolism and kinetics. Cancer Res 1995; 55 Suppl.: 5777–85
Abdel-Nabi H, Doerr RJ. Indium-111 labeled MoAb detection of liver metastasis from colorectal cancer: histopathological and immunoscintigraphic correlates. Eur J Nucl Med 1990; 16 Suppl.: 101